Menu
Back to User profile » Dr Weiqi Dai
Papers published by Dr Weiqi Dai:
Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma
Yu Q, Wu L, Ji J, Feng J, Dai W, Li J, Wu J, Guo C
Journal of Hepatocellular Carcinoma 2020, 7:271-288
Published Date: 29 October 2020
Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2
Liu T, Li S, Wu L, Yu Q, Li J, Feng J, Zhang J, Chen J, Zhou Y, Ji J, Chen K, Mao Y, Wang F, Dai W, Fan X, Wu J, Guo C
Journal of Hepatocellular Carcinoma 2020, 7:19-31
Published Date: 18 February 2020
Inhibitive effects of 15-deoxy-Δ12,14-prostaglandin J2 on hepatoma-cell proliferation through reactive oxygen species-mediated apoptosis
Chen K, Dai W, Wang F, Xia Y, Li J, Li S, Liu T, Zhang R, Wang J, Lu W, Zhou Y, Yin Q, Zheng Y, Abudumijiti H, Chen R, Lu J, Zhou Y, Guo C
OncoTargets and Therapy 2015, 8:3585-3593
Published Date: 1 December 2015
Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta-analysis
Zhang H, Yang J, Zhu R, Zheng Y, Zhou Y, Dai W, Wang F, Chen K, Li J, Wang C, Li S, Liu T, Abudumijiti H, Zhou Z, Wang J, Lu W, Wang J, Xia Y, Zhou Y, Lu J, Guo C
Drug Design, Development and Therapy 2015, 9:567-574
Published Date: 17 January 2015
Hydrogen sulfide, a potential novel drug, attenuates concanavalin A-induced hepatitis
Cheng P, Chen K, Xia Y, Dai WQ, Wang F, Shen M, Wang C, Yang J, Zhu R, Zhang H, Li JJ, Zheng Y, Wang J, Zhang Y, Lu J, Zhou YQ, Guo CY
Drug Design, Development and Therapy 2014, 8:1277-1286
Published Date: 9 September 2014